Objective: Obesity is an enormous burden for patients and health systems world-wide. Brown adipose tissue dissipates energy in response to cold and has been shown to be metabolically active in human adults. The type I transforming growth factor b (TGFb) receptor Activin receptor-like kinase 7 (Alk7) is highly expressed in adipose tissues and is down-regulated in obese patients. Here, we studied the function of Alk7 in brown adipocytes. Methods: Using pharmacological and genetic tools, Alk7 signaling pathway and its effects were studied in murine brown adipocytes. Brown adipocyte differentiation and activation was analyzed. Results: Alk7 is highly upregulated during differentiation of brown adipocytes. Interestingly, Alk7 expression is increased by cGMP/protein kinase G (PKG) signaling, which enhances brown adipocyte differentiation. Activin AB effectively activates Alk7 and SMAD3 signaling. Activation of Alk7 in brown preadipocytes suppresses the master adipogenic transcription factor PPARg and differentiation. Stimulation of Alk7 during late differentiation of brown adipocytes reduces lipid content and adipogenic marker expression but enhances UCP1 expression. Conclusions: We found a so far unknown crosstalk between cGMP and Alk7 signaling pathways. Tight regulation of Alk7 is required for efficient differentiation of brown adipocytes. Alk7 has differential effects on adipogenic differentiation and the development of the thermogenic program in brown adipocytes.
INTRODUCTION
Obesity is not only an esthetic, but a major health issue with a steadily growing, global prevalence. Health consequences of overweight and obesity include diabetes, cardiovascular diseases and some types of cancer. Presently, there are only few drugs that can be used to treat obesity. Brown adipose tissue (BAT) has emerged as a potential target for the development of novel anti-obesity drugs. BAT dissipates energy in the form of heat upon cold exposure or b-adrenergic stimulation [1e 4]. b-adrenergic signaling induces break-down of triglycerides to free fatty acids (FFA) and glycerol. The FFA serve as fuel for the mitochondrial uncoupling protein 1 (UCP1), which disrupts the proton gradient through the inner mitochondrial membrane, thereby funneling energy to produce heat instead of ATP in brown adipocytes (BA). Taken together, activation of BAT leads to increased energy expenditure, which has positive effects on whole-body metabolic homeostasis. The delineation of regulatory pathways would be an important basis for development of novel BAT-centered therapies. Recently, cyclic guanosine monophosphate (cGMP) was identified as a major factor that controls adipogenic and thermogenic differentiation of brown adipocytes [5e7] . The effects of cGMP in BAT are mediated by protein kinase G (PKG) [7, 8] . The transforming growth factor-b (TGF-b) superfamily has been implicated in different biological processes including tumor growth and white adipose tissue inflammation amongst others [9, 10] . The type I TGFb receptor Activin receptor-like kinase 7 (Alk7) is highly expressed in adipose tissues of rodents and humans [11, 12] . Interestingly, Alk7 expression is reduced in obese patients and negatively correlates with clinical parameters of metabolic disease [11] , indicating that Alk7 is relevant for the maintenance of a healthy lean state. Moreover, global Alk7 knockout mice are partially resistant to diet-induced obesity in comparison to their wildtype (wt) littermates [13] but develop insulin resistance and liver steatosis [14] . The TGFb receptor family is heterogenous and its receptors can be activated by a plethora of ligands. Known ligands for Alk7 are Nodal [15] , GDF11 [16] , GDF3 [13] and Activin AB and B [17] . After ligand binding, SMAD2 and 3 are phosphorylated by Alk7 as shown in rat PC12 pheochromocytoma cell line [18] , murine MIN6 insulinoma cells [19] and the murine white adipocyte cell line 3T3-L1 [20] . Phosphorylated SMADs form complexes with the cofactor SMAD4 and regulate gene expression together with additional transcription factors [21] . In addition to the canonincal SMAD2/3 pathway, SMADindependent pathways of Alk7 signaling include MAPK, RhoA/ROCK, AKT/PI3K and Wnt/b-Catenin pathways [22] . So far, studies of Alk7 focused on its role in white adipose tissue. Here, we investigated its role in brown adipocytes and a possible interplay of cGMP with Alk7 signaling. We found that Alk7 expression is regulated by cGMP/PKG pathway. Alk7 activation differentially regulates adipogenic and thermogenic differentiation of brown adipocytes.
MATERIAL AND METHODS

Adipogenic differentiation Stromal vascular fraction (SVF) cells isolated from BAT of wt or PKGI
À/À mice were immortalized and differentiated into mature brown adipocytes as described previously [7, 8, 23, 24] . In short, immortalized SVF cells were seeded and cultured in growth medium [DMEM supplemented with 5% fetal bovine serum (FBS), 1% penicillin/streptomycin (P/S)]. Two days after seeding (day À2) the medium was exchanged to differentiation medium (growth medium supplemented with 20 nM insulin and 1 nM triiodothyronine). Differentiation was induced two days later (day 0) by replacing the medium with induction medium (differentiation medium supplemented with 0.5 mM isobutylmethylxanthine and 1 mM dexamethasone) for 48 h. Until day 7 post induction the medium was replenished with differentiation medium every second day. Treatment with either 200 mM 8-Br-cGMP or 8-pCPT-cGMP started on day À2.
Chronic Activin AB (both 10 ng/ml) treatment started on day À2 or day 4 of differentiation, as indicated in the respective experiments. For SMAD3 phosphorylation experiments cells were acutely treated with Activin AB or Activin B (10 ng/ml) for 60 min on day 0 or day 7 of differentiation.
Lentiviral plasmids and transduction of brown adipocytes
Lentiviral vectors were obtained either by cloning wt (LV-Alk7) or constitutively active (LV-caAlk7; kindly provided by Chun Peng) human Alk7 into the Bam HI and Sal I sites of the vector p156rrlsinPPTCMV, which carries a cytomegalovirus promoter. The control vector (p156rrlsinPPT) contained neither promoter nor transgene (LV-ctrl). The production of lentiviruses and infection of cells were performed as previously described [7, 8, 23] . In brief, cells were seeded on six-well plates. After 8 h, the medium was changed to medium containing amounts of lentivirus corresponding to 50 ng of viral reverse transcriptase per six-well plate, and incubated overnight. Adipogenic differentiation was performed as described above. 
Western blot analysis
Protein lysates were prepared as previously described [7, 8] with radioimmunoprecipitation assay buffer supplemented with protease inhibitor cocktail Complete (Roche), 1 mM Na 3 VO 4 , and 10 mM NaF. Protein contents were determined by the Bradford method. Western blotting was performed as described previously [7, 8] . The following antibodies were used: antibodies against aP2, and PPARg from Santa Cruz Biotechnology; antibodies against PSMAD3, SMAD3, HSL, ATGL from Cell Signaling Technology; antibody against UCP1 from Sigmae Aldrich and antibodies against Tubulin (Dianova). Secondary horse radish peroxidaseelinked antibodies against goat (Pierce), mouse (Dianova), and rabbit (Cell Signaling) were used. All bands were quantified by densitometric analysis with Image J software.
2.7. Luciferase reporter assays HIB1B cells were transiently cotransfected with firefly and Renilla luciferase expression vectors using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. 24 h after transfection cells were treated with Activin AB or B (10 ng/ml) for another 18 h. Luciferase assays were performed with the Dual-Luciferase Reporter Assay System (Promega) according to the assay protocol. Cell lysates were prepared following the manufacturer's instructions. The activity of the firefly luciferase was normalized to the corresponding Renilla activity value for each sample. The 2000bp Alk7 promoter was divided into three subunits (0e1000bp ¼ Alk7A; 500e1500bp ¼ Alk7B; 1000e2000bp ¼ Alk7C) and each subunit was cloned into the pGL3-basic luciferase vector. The UCP1 (pGL3-basic) promoter luciferase construct was kindly obtained by Dr. Stephan Herzig, Deutsches Krebsforschungszentrum, Heidelberg. Vectors without promoter were used as a negative control. The internal control was pRL-TK vector (Promega) expressing Renilla luciferase under the control of the herpes simplex virus thymidine kinase (TK) promoter.
Statistical analysis
Values are presented as means AE SEM. Statistical differences among multiple groups were determined using oneway analysis of variance (ANOVA) with NewmaneKeuls Multiple Comparison Test, unless otherwise indicated. Unpaired, two-tailed student's t-tests were used for single-comparisons. GraphPad Prism 5 was used to calculate Pvalues.
RESULTS
Alk7 expression increases during brown adipocyte differentiation and is modulated by cGMP/PKGI
To study Alk7 expression during BA differentiation, we used preadipocytes isolated from newborn mice and differentiated them to mature BA (Suppl. 1). Alk7 expression was significantly upregulated between day 4 and day 7 of differentiation reaching a 17-AE 2.5-fold increase at day 6 of differentiation in comparison to undifferentiated preadipocytes (day À2) ( Figure 1A ). Mature BA (day 7) showed an 8.3-AE 1.3-fold higher expression of Alk7 than preadipocytes ( Figure 1A) . In comparison to Alk7, the expression level of PPARg significantly increased already at day 2 of differentiation and exhibited no significant further upregulation until the end of differentiation (Suppl. 1B).
To study whether enhanced differentiation is correlated with Alk7 expression, we treated the cells with cGMP, which enhances differentiation of BA [7] . cGMP treatment increased Alk7 mRNA expression 2.1-AE 1.2-fold and 50.2-AE 17.6-fold in preadipocytes and in mature BA, respectively, compared to the untreated control ( Figure 1B) . Interestingly, Alk7 mRNA expression was reduced by 95 AE 3.9% in mature BA deficient for PKGI (PKGI À/À ) as compared to wt BA ( Figure 1C ) indicating that cGMP signaling controls also basal Alk7 levels in BA. To further examine the mechanism of cGMP/PKGIdependent regulation of Alk7 expression, the Alk7 promoter was divided into three different parts and cloned into a luciferase reporter backbone ( Figure 1D ). Luciferase assays were performed in the BA cell-line HIB1B in the presence and absence of cGMP. The 3 0 part of the Alk7 promoter (Alk7C) exhibited the highest luciferase activity under basal conditions and cGMP treatment significantly enhanced Alk7C promoter activity by 36%, whereas the other (5 0 and middle part) elements of the promoter did not respond to cGMP ( Figure 1E ). These data show that Alk7 expression increases during differentiation and that Alk7 expression is regulated by the cGMP/PKGI signaling pathway at the transcriptional level. (Figure 2A) . Expression of the individual ligands was not significantly changed during BA differentiation (Figure 2A) . Nevertheless, we observed major differences in expression levels of the potential Alk7 ligands (Inhibin bA > GDF11 > Inhibin bB >> GDF3 > Nodal) (Figure 2A ). Inhibin bA showed the highest expression levels (ca. 300-fold higher in comparison to Nodal), followed by GDF11 (>130-fold in comparison to Nodal) and Inhibin bB (more than 50-fold in comparison to Nodal) ( Figure 2A ). GDF11 is a weak ligand for Alk7 and has previously been shown to predominantly signal via Alk4 and Alk5 [11] . Therefore, we focused on Activin AB 
Early activation of Alk7 diminishes adipogenic differentiation
Next, we studied the effect of early activation of Alk7 with Activin AB starting at the preadipocyte stage (day À2 to day 7). Treatment with both Activin AB or B induced phosphorylation of SMAD3 in ctrl and LV- ctrl preadipocytes albeit not significantly ( Figure 2D , E). Preadipocytes overexpressing LV-Alk7 responded to Activin AB with a significant increase in PSMAD3 ( Figure 2D, E) . Notably, early Activin treatment suppressed adipogenic differentiation as seen in Oil Red O stainings ( Figure 2F ). This was confirmed by analysis of PPARg, aP2 and UCP1 protein levels. PPARg and aP2 were reduced by 82 AE 1.9% and 79 AE 0.5%, respectively ( Figure 2G , H). UCP1 was reduced by 90 AE 2.7% in comparison to untreated cells ( Figure 2I ). Transduction of preadipocytes with LV-caAlk7 suppressed differentiation with a significant reduction of PPARg expression by 70 AE 17.2% (Suppl. 2C). These data show that basal levels of SMAD3/ Alk7 signaling are low in preadipocytes and that early activation of Alk7 or expression of a constitutively active Alk7 suppresses expression of PPARg and adipogenic differentiation.
Differential effects of Alk7 on adipogenic and thermogenic programs in mature BA
To study the role of Alk7 signaling in mature BA, we activated Alk7 during the last three days of differentiation (day 4 to day 7) using Activin AB. Activin AB treatment of mature BA reduced intracytoplasmic lipid content as shown by reduced Oil Red O staining ( Figure 3A) . Furthermore, Activin AB treatment significantly reduced protein levels of the adipogenic markers PPARg and aP2 ( Figure 3B , C), as well as of the lipases HSL and ATGL ( Figure 3D , E). Lipolysis is an important parameter of BA function, because it liberates FFA that activate UCP1 and serve as fuel for thermogenesis. We found a significantly reduced lipolysis in Activin AB treated BA under basal conditions ( Figure 3F ) as well as after norepinephrine stimulation (Suppl. 2D). Unexpectedly, activation of Alk7 increased the protein levels of the thermogenic marker UCP1 more than 1.6-fold ( Figure 3G ). To further analyze this effect of Alk7 on UCP1 levels, we studied UCP1 promoter activity in HIB1B cells. Cells were transfected with vectors carrying Alk7 or caAlk7 or a control vector and treated with Activin AB.
Overexpression of Alk7 alone induced a significant upregulation of the UCP1 promoter activity by 1.7-AE 0.1-fold. Activin AB treatment caused a 1.9-AE 0.2-fold increase as compared to untreated control ( Figure 3H ). caAlk7 transfection also resulted in a 1.9-AE 0.2-fold increase in UCP1 promoter activity, comparably to Alk7 overexpression ( Figure 3I ). These data demonstrate that Alk7 negatively regulates the adipogenic program but enhances the thermogenic program by activation of UCP1 transcription in BA.
3.5. Effect of Alk7 on cGMP-mediated regulation of adipogenic and thermogenic programs cGMP facilitates adipogenic and thermogenic differentiation of BA [7] . Simultaneous activation of Alk7 by Activin AB and cGMP signaling from day 4 to day 7 reduced cGMP effects on adipogenesis as seen in Oil Red O stainings ( Figure 4A ). Furthermore, Activin AB treatment significantly reduced the effects of cGMP on PPARg and aP2 expression by 44% and 36.5% respectively (Figure 4B , C). Alk7 signaling had a similar inhibitory effect on the cGMP-induced increase of HSL and ATGL expression ( Figure 4D, E) . Strikingly, Activin AB and cGMP had additive effects on UCP1 protein expression. cGMP treatment alone lead to a 3.8-AE 0.6-fold increase in UCP1 expression as compared to untreated control cells. Combination of Activin AB and cGMP treatment increased UCP1 protein levels to 8.1-AE 1.7-fold in comparison to untreated control ( Figure 4F ). In conclusion, cGMP effects on the adipogenic program are counteracted by Alk7 activation, whereas UCP1 expression is positively enhanced.
DISCUSSION
4.1. Alk7 expression is modulated by cGMP/PKGI Only a few years ago, metabolically active BAT was found to be present in human adults [25] . It is estimated that BAT activity is responsible for ca. 5% of daily basal metabolic rate in humans. If activated this would correspond to the dissipation of about 4 kg of white fat per year [26, 27] . Therefore, BAT attracted a lot of attention as a way to increase energy expenditure in order to fight the rising prevalence of obesity. The second messenger cGMP acts through PKGI to facilitate adipogenic and thermogenic differentiation of BAT [7] . cGMP regulates BA differentiation through different pathways: (i) cGMP inhibits Rho/ROCK activity, thereby enhancing insulin signaling in BA [7] . (ii) cGMP increases UCP1 and PPARg transcription [7] . (iii) Here, we show that the TGFb type I receptor Alk7 is regulated by the cGMP/PKGI signaling pathway, thus, identifying a so far unknown interaction of the cGMP/ PKGI with the TGFb pathway in BA. Alk7 is expressed at very low levels in brown preadipocytes and expression is significantly upregulated 4 days after induction of differentiation. Treatment with cGMP further enhances Alk7 expression in BA. This effect is blunted in PKGI À/À adipocytes and caused by an increase in Alk7 promoter activity. Moreover, basal Alk7 levels in PKGI À/À BA are reduced to w5% of the levels observed in wt cells.
The type of cGMP-dependent Alk7 regulation is different from the previously reported direct interaction of PKGI with the TGFb family member bone morphogenetic protein (BMP) receptor [28] .
4.2. Alk7 acts as a potential brake for cGMP effects on adipogenic differentiation Several ligands for Alk7 have been described including Nodal [15] , GDF11 [16] , GDF3 [13] and Activin AB and B [17] . We found, that the subunits of Activins, i.e. Inhibin bA and Inhibin bB, are most highly expressed in BA. Activin AB induced SMAD3 phosphorlyation most efficiently demonstrating that Alk7 signaling occurs through the canonical pathway in BA. Alk7-mediated activation of SMAD3 significantly reduced abundance of the master adipogenic transcription factor PPARg in BA, which is induced in early adipogenesis. Stimulation of Alk7 during early differentiation had a deleterious effect and abrogated BA differentiation due to the significantly reduced expression of PPARg. Interestingly, reduced PPARg expression was only seen after activation of Alk7 by Activins, whereas sole overexpression of Alk7 did not change PPARg levels indicating that Alk7 expression and activation needs to be tightly regulated during BAT differentiation. It was shown previously that activated SMAD3 suppresses PPARg expression in the 3T3-L1 white adipocyte cell line. The underlying mechanism for SMAD3-dependent regulation of PPARg is the interaction of SMAD3 with C/EBP and the subsequent repression of C/EBPmediated transcription of PPARg promoter [29] . Moreover, Yogosawa et al. have shown that SMAD3 disrupts the positive feedback loop between the adipogenic master regulators PPARg and C/EBPa in white adipocytes [20] . Alk7 activation during the end/late stage of differentiation (last 3 days of adipogenesis) resulted in differential effects on the adipogenic and thermogenic programs of BA. Abundance of adipogenic markers, lipid content and lipolysis was significantly reduced in Activin AB treated cells. In line with these findings, Guo et al. recently published that Activin B treatment of mouse embryonic fibroblast (MEF) during differentiation to white adipocytes results in reduced levels of PPARg and HSL, as well as reduction of lipolysis [30] . Unexpectedly, we found that protein expression of UCP1 is upregulated after Alk7 activation in BA, by enhancing UCP1 promoter activity through SMAD activation.
The differential effects of Alk7 in mature BA were especially pronounced after cGMP treatment. On one hand, we propose that Alk7 acts as a potential safety mechanism to ensure that overstimulation of the adipogenic program by cGMP is avoided. On the other hand, Alk7 activation together with cGMP treatment had an additive effect on UCP1 expression and doubled the amount of UCP1 protein as compared to cGMP treatment alone. In obese patients with decreased Alk7 expression [11] , it could be of clinical interest to enhance cGMP signaling in BAT to endogenously increase Alk7 expression and boost UCP1 activity.
CONCLUSION
The type 1 TGFb receptor Alk7 is highly expressed in BA. We found that Alk7 and cGMP/PKGI signaling are tightly connected in BA to ensure a balance between the adipogenic and thermogenic program e favoring the thermogenic capabilities of BA if Alk7 is activated together with cGMP. Understanding the link between the cGMP/PKGI and Alk7 signaling pathway could proof beneficial when looking for new targets for anti-obesity drug development.
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